Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Capital Expenditures (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Capital Expenditures for 14 consecutive years, with $668000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 3.61% to $668000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 63.03% decrease, with the full-year FY2023 number at $8.5 million, up 70.85% from a year prior.
  • Capital Expenditures was $668000.0 for Q3 2025 at Gyre Therapeutics, up from $256000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.5 million in Q2 2023 to a low of $122000.0 in Q1 2025.
  • A 4-year average of $1.1 million and a median of $693000.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 152.31% in 2021, then tumbled 86.74% in 2024.
  • Gyre Therapeutics' Capital Expenditures stood at $492000.0 in 2021, then skyrocketed by 372.36% to $2.3 million in 2023, then tumbled by 70.18% to $693000.0 in 2024, then dropped by 3.61% to $668000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Capital Expenditures are $668000.0 (Q3 2025), $256000.0 (Q2 2025), and $122000.0 (Q1 2025).